How do brain-computer interface companies make money today?

What actually counts as BCI revenue today?

BCI revenue today mostly comes from products and services that customers can already buy: research hardware, EEG systems, software, cloud tools, clinical services and a small number of adjacent medical devices.

That definition matters because the biggest names in brain-computer interfaces can otherwise look far more commercial than they really are. A $650 million financing round gives a company a lot of cash, but it does not tell us whether anyone is paying for its BCI. A $650 million round says little about paying customers, so we separate who makes money from who burns cash in our neurotech report.

For this analysis, we count money paid by customers for neurotechnology products or services. Venture funding and grants still matter because they keep companies alive through long development cycles, but we treat them separately from revenue.

Once we make that distinction, the market becomes much easier to read. Neuralink, Synchron and Paradromics are currently building implanted systems through clinical trials. Blackrock Neurotech already sells neural-recording equipment. Emotiv and OpenBCI sell non-invasive research hardware. Kernel charges for brain-imaging infrastructure and cloud services. Muse sells consumer neurotechnology and subscriptions. ONWARD Medical already earns revenue from spinal-cord stimulation while developing a brain-controlled system.

The money is therefore spread across very different businesses that happen to sit under the BCI label.

Company	What brings in money now?	Is its main implanted BCI commercially available?	Where the business sits today
Neuralink	Mainly equity funding	No	Human clinical development
Synchron	Mainly equity funding	No	Human clinical development
Paradromics	Equity and research funding	No	Early human clinical development
Precision Neuroscience	Funding plus a commercially cleared cortical array	Full BCI: no	Early commercialization + BCI development
Blackrock Neurotech	Neural research hardware and software	MoveAgain: no	Established research supplier
Emotiv	EEG hardware, software and developer tools	Not applicable	Commercial research platform
OpenBCI	EEG and multimodal research hardware	Not applicable	Commercial research hardware
Kernel	Neuroimaging systems and cloud services	Not applicable	Neuroscience infrastructure
Muse	Consumer brain-sensing hardware and subscriptions	Not applicable	Consumer neurotechnology
ONWARD Medical	Commercial neurostimulation systems	ARC-BCI: no	Commercial MedTech + BCI development

Are Neuralink, Synchron and Paradromics making money from their brain implants yet?

Neuralink, Synchron and Paradromics are not currently running normal commercial implant businesses; their flagship BCIs are still investigational devices being tested in people.

Neuralink is further into human deployment than it was even a year ago. The company now reports 21 participants across its clinical programs, and its latest technical work describes training neural decoders on 50,000 hours of unlabeled brain data. Those numbers show that Neuralink is moving beyond one-off demonstrations and building a much larger clinical and data operation.

They still do not represent ordinary product sales.

Synchron is in the same broad position commercially. Its Stentrode has been implanted in people for years, including participants with unusually long follow-up, but the system remains investigational rather than a routinely purchased medical device.

Paradromics has moved quickly lately. Its first participant in the Connect-One study received the long-term Connexus implant earlier in 2026, and the company subsequently demonstrated real-time, open-ended speech and text communication from that participant's neural activity. The FDA has also allowed the study to expand from a company-controlled computing setup to compatible personal laptops, tablets and phones.

That is meaningful commercial preparation. A BCI that can eventually work with devices people already use is much easier to imagine selling than a system locked to laboratory hardware. But Paradromics still describes Connexus as an investigational device.

So the leading implanted BCI companies are currently proving that the technology can work repeatedly in real humans. They have not yet reached the stage where thousands of patients or hospitals are paying for it.

If implanted BCIs are not selling yet, who is paying the bills?

Investors are still paying most of the bills for the major implanted BCI startups.

The amounts are already enormous. Neuralink raised $650 million in its Series E. Synchron later raised another $200 million. Precision Neuroscience recently closed a $250 million Series D after already raising substantial capital in earlier rounds.

These financings make sense when we look at what companies have to pay for before meaningful sales arrive. An implanted BCI requires far more than electrodes and a decoder. Companies have to build implantable electronics, manufacturing processes, surgical tools, clinical teams, trial sites, regulatory systems, long-term participant support and software that keeps working after implantation.

Paradromics' Connect-One study makes the burden unusually visible: participants are expected to remain in the study for six years and work repeatedly with the clinical team as the system is adjusted and evaluated.

There is a strange economic inversion here. The implanted systems attracting the most capital currently produce the least obvious product revenue, while much smaller non-invasive neurotechnology companies can sell something immediately.

That gap is one of the defining features of the BCI market today.

Which BCI companies can actually sell you something right now?

The easiest BCI companies to monetize today are the ones selling research and non-invasive systems, because customers can buy the hardware without waiting for brain surgery or reimbursement.

OpenBCI provides probably the clearest public price ladder. Its eight-channel Cyton biosensing board currently costs $1,249. A complete Ultracortex system starts around $2,999. Its All-in-One Biosensing R&D Bundle costs $4,499. At the top end, the Galea multimodal research headset is listed at $42,980.

That range alone tells us something important about the market. "BCI hardware" can mean a relatively affordable developer board or a research system costing more than many cars.

Emotiv covers another part of the same market. Its current lineup includes the $399 MN8 EEG headphones, the $499 Insight, the $1,199 14-channel Epoc X and higher-channel Flex systems in roughly the $2,000-plus range.

Blackrock Neurotech sits further toward specialist neuroscience. The company says its neural technologies are used in more than 1,000 laboratories across 53 countries and have supported neural-interface research since 2004.

These companies are selling access to brain signals long before most end users can buy a brain-controlled computer. Universities, hospitals, product developers and neuroscience teams are already willing to pay for the equipment needed to collect those signals.

Why do researchers pay so much for BCI hardware?

Researchers pay thousands or even tens of thousands of dollars for BCI hardware because reliable neural data are the starting point for almost everything else in the industry.

A developer cannot train a useful decoder without data. A university cannot run a BCI experiment without sensors and acquisition hardware. A pharmaceutical company studying changes in brain activity also needs trustworthy measurements.

That turns the research bottleneck itself into a business. Researchers paying to get past their data bottleneck is one source of revenue, and we ask where else it could come from in our report covering neurotech.

OpenBCI can sell a $42,980 Galea system because it combines several biosignals in one research platform. Blackrock can sell more specialized neural equipment because laboratories working on intracortical interfaces need hardware that can record tiny electrical signals reliably over many channels. Emotiv reaches customers that need something cheaper and easier to deploy.

There is also far less friction in selling to a research lab than in selling an implanted medical device. A researcher can obtain a budget, order equipment and begin collecting data. An implant manufacturer may need years of clinical evidence before routine patient sales are possible.

Research infrastructure is one of the few BCI business models that has already survived long enough to prove itself.

Can consumer EEG devices become a real BCI business?

Consumer EEG can already support a real business, although the economics currently look much closer to premium wearables than to the futuristic BCI market people often imagine.

Muse is a useful example because the company has reached a much broader user base than implant developers. It says more than 500,000 people have used its products. The Muse 2 currently costs about $250, while the more advanced Muse S Athena sits above $500 when bundled with Premium.

Neurable is trying another route by putting EEG into a familiar product category. Its brain-sensing headphones are sold as headphones first, with neural sensing layered into the experience.

Emotiv also operates near this boundary. Its lower-priced systems can be bought by individual developers and enthusiasts, while its larger systems are aimed more directly at professional research.

The attraction is obvious: a company can ship thousands of devices without neurosurgery, hospital purchasing committees or medical reimbursement.

The ceiling may also be lower. People compare a $300 or $500 neural wearable with headphones, smartwatches and fitness trackers. A medical implant that restores communication to someone who cannot speak sits in a completely different value bracket.

Consumer BCI can probably reach scale sooner. Medical BCI has a much better chance of producing very high revenue per patient.

Why are BCI companies charging subscriptions on top of the hardware?

BCI companies are increasingly charging recurring fees because the useful product often continues after the headset or scanner has been sold.

Emotiv makes the model easy to see. Its Epoc X costs around $1,199, while a Standard EmotivPRO license currently costs $89 per month when billed annually. A university buying an Epoc X research bundle is therefore buying both a physical device and a year of professional software.

Kernel does something similar in a more expensive research environment. Researchers using Kernel Flow can manage data locally for free, while Kernel Cloud Pro costs $400 per system per month, or $360 per month with an annual subscription. Recording and storage beyond the included allowances are billed separately.

Muse uses the consumer version of the model. Its basic hardware works without Premium, while more advanced sleep, focus and coaching features sit behind a roughly $50 annual subscription.

The recurring layer fits BCI unusually well. Neural devices continuously produce data, and customers often need storage, visualization, analysis, APIs, model updates and collaboration tools after the hardware arrives.

Company	Hardware or platform	Recurring product	Current public price
Emotiv	Epoc X EEG headset	EmotivPRO Standard	$89/month billed annually
Emotiv	Research bundles	Annual research software	Bundled into research packages
Kernel	Flow research system	Kernel Cloud Pro	$400/system/month
Kernel	Flow research system	Cloud recording overage	$4/hour on Pro
Kernel	Flow research system	Cloud storage overage	$0.40/hour/month on Pro
Muse	Muse 2	Premium	About $50/year
Muse	Muse S Athena	Premium	About $50/year
Neurosity	Crown	Membership	Recurring membership model

Are BCI companies going to make money from selling brain data?

Brain data are becoming extremely valuable to BCI companies, but the stronger business today is selling tools around the data rather than selling the recordings themselves.

Neuralink's latest technical update is a good illustration. The company says it pretrained neural decoders using 50,000 hours of unlabeled brain data and reached an 11.32 bits-per-second performance record. Whatever one thinks about the eventual product, a dataset of that scale can help Neuralink build better decoders and reduce the need for constant recalibration.

That gives the data strategic value.

Kernel monetizes a more straightforward layer by charging researchers to record and store brain-imaging data in its cloud. Emotiv charges for professional recording, analysis and export tools. Blackrock sells the hardware that researchers use to create neural datasets in the first place.

Those are cleaner businesses than trying to resell identifiable neural recordings.

Privacy and regulation will also make raw brain-data markets difficult. Neural information can reveal far more sensitive characteristics than ordinary device telemetry, while clinical datasets may fall under additional medical and research rules.

For now, the best commercial use of proprietary brain data is improving the product customers already pay for.

Can pharma companies become big customers for BCI technology?

Pharma could become one of the more lucrative BCI-adjacent customer groups because drug developers have reasons to measure the brain even when nobody is trying to control a computer.

A company developing a psychiatric or neurological drug wants to know whether treatment changes brain activity. Traditional clinical endpoints can be slow, subjective or noisy. Neuroimaging and electrophysiology can potentially add another layer of evidence. Drug developers who need proof that a treatment changes brain activity may become customers; we map where the openings are in our neurotech business models report.

Kernel is already positioning Flow around that opportunity. Its platform gives researchers a non-invasive way to measure brain activity while its cloud handles data collection and storage. The company has also worked on studies involving psychoactive, neuropsychiatric and neurocognitive interventions.

Emotiv similarly markets EEG systems to academic, clinical and commercial researchers rather than only to people building cursor-control BCIs.

Blackrock has spent decades inside neuroscience laboratories where the customer is often the research institution rather than the eventual patient.

The addressable budget changes when the buyer becomes a pharmaceutical company running a clinical program instead of an individual buying a headset. A small number of serious research contracts can be worth far more than thousands of consumer subscriptions.

This part of the market is still less visible than Neuralink-style implants, but commercially it deserves much more attention.

Has Precision Neuroscience already crossed into commercial BCI?

Precision Neuroscience has crossed an important commercial threshold, but its full brain-computer interface is still not a normal commercial product.

The FDA cleared Precision's Layer 7 Cortical Interface for recording, monitoring and stimulating electrical activity on the brain surface for periods of up to 30 days. Precision explicitly describes the clearance as opening the door to commercial use of that component.

That is different from Neuralink, Synchron or Paradromics simply having permission to run an investigational clinical study.

Precision can now commercialize a piece of its technology for approved uses while it continues developing the complete implantable BCI. The company has also been building hospital relationships and recently announced a partnership with Medtronic to integrate Layer 7 with Medtronic's neurosurgical platform.

The latest $250 million financing reinforces the direction: Precision is preparing for a much larger commercial operation rather than merely funding another laboratory prototype.

Still, we should keep the distinction clean. A temporary cortical electrode array cleared for clinical use is not the same product as Precision's intended long-term wireless BCI.

Precision is currently one of the closest examples we have of a BCI company moving from pure development into partial commercialization.

Who will actually pay for implanted BCIs when they launch?

Hospitals, insurers and public healthcare systems are likely to control much of the implanted BCI market because the first products target severe medical conditions rather than healthy consumers.

Look at the patients being recruited today. Neuralink is working with people with paralysis and severe speech impairment. Paradromics is testing Connexus in people whose neurological conditions have severely affected speech. Synchron has focused on people with major motor impairment.

These patients are unlikely to pay the full cost of an implant, neurosurgery, hospitalization, programming and long-term support out of pocket. Patients are unlikely to cover an implant, surgery and support themselves; we look at who pays, and for what, in our report on neurotech.

The U.S. reimbursement machinery is already starting to move. CMS recently published a request for a dedicated ICD-10-PCS procedure code covering insertion of a brain-computer interface device because no unique code currently exists. The request seeks implementation in 2027, and the requestor also indicated plans to pursue a New Technology Add-on Payment application.

That may sound administrative compared with a person controlling a cursor with thought, but it is one of the clearest signs that implanted BCI is approaching a real commercial question.

A hospital needs to know how a procedure is coded. A payer needs to know what it is reimbursing. A BCI company needs both before large-scale sales become realistic.

How much could one implanted BCI patient be worth?

One successful implanted BCI patient could eventually generate far more revenue than one consumer EEG customer because the medical product includes surgery, specialized hardware and years of support.

There is no reliable commercial price for Neuralink, Synchron or Paradromics yet, so pretending we know the eventual dollar amount would be guesswork.

Existing implanted neurotechnology gives us a better reference point.

NeuroPace sells an FDA-approved brain-responsive neurostimulation system for epilepsy. The company generated $100 million of total revenue in 2025, including $81.7 million from its RNS System, and reported an 81.9% gross margin on RNS revenue.

NeuroPace is not a computer-control BCI company. What it proves is that an implanted system that records neural activity, interprets it and responds therapeutically can become a real medical-device business with revenue measured in tens of millions of dollars and strong product margins.

The comparison with consumer BCI is stark. Muse sells hardware for hundreds of dollars. Emotiv's mainstream research headsets sell for hundreds to a few thousand dollars. A medically necessary implanted platform can support a completely different revenue structure.

The hard part is getting there.

Can grants keep BCI companies alive before sales arrive?

Grants can meaningfully extend a BCI company's runway, but they cannot replace a commercial market forever.

ONWARD Medical shows the distinction particularly well because its accounts separate product revenue from grant income. In 2025, ONWARD reported €5.4 million of total revenue, including €3.7 million from ARC-EX system sales, while other income, mainly grants, was another €1.7 million.

Some of that research support has funded its brain-computer-interface work. ONWARD's ARC-BCI program combines cortical signals with spinal-cord stimulation in an effort to restore thought-driven movement.

Government agencies and foundations have good reasons to fund this type of work. BCI research sits at the intersection of neuroscience, disability, rehabilitation, artificial intelligence and advanced medical devices, while commercial returns may still be many years away.

Paradromics has also received NIH support during development, and academic BCI programs frequently depend on public research budgets.

Grant money therefore does useful economic work: it lets companies generate evidence without financing every experiment through equity.

A company that remains permanently dependent on grants, however, has not demonstrated a commercial business. Eventually someone has to pay for the product.

Why are some BCI companies selling another neurotechnology product first?

Selling a simpler neurotechnology product first gives BCI companies revenue, customers and commercial experience while the harder implant is still being developed.

ONWARD Medical is probably the best current example.

Its ARC-BCI system for thought-driven movement remains investigational, but ONWARD already sells ARC-EX, a non-invasive spinal-cord stimulation device. During its first full commercial year, the company sold 117 ARC-EX systems to more than 80 U.S. clinics and generated €3.7 million from system sales. Including other commercial revenue, total revenue reached €5.4 million.

At the same time, seven people had received experimental ARC-BCI implants.

That means ONWARD can learn how to sell neurotechnology to clinics, train healthcare professionals, manufacture at commercial quality, handle reimbursement and support patients before ARC-BCI itself is ready.

Blackrock follows a different version of the same playbook. Its future medical BCI ambitions sit on top of a research business that already supplies more than 1,000 laboratories.

Precision is beginning to create another version through the cleared Layer 7 cortical array while its full implant remains in development.

This "sell something useful first" strategy currently looks much more robust than asking investors to finance an entire company until the ultimate BCI reaches the market.

Company	Product already usable commercially	Bigger BCI ambition	What the first business provides
ONWARD Medical	ARC-EX spinal stimulation	ARC-BCI	Clinic relationships and medical-device sales
Blackrock Neurotech	Research neural hardware	MoveAgain BCI	Long-running research revenue and users
Precision Neuroscience	Cleared Layer 7 cortical array	Fully implantable BCI	Hospital access and early commercialization
Emotiv	EEG hardware and software	Wider BCI applications	Research and developer revenue
OpenBCI	Research biosensing systems	More advanced multimodal interfaces	Installed research ecosystem
Kernel	Brain-imaging systems and cloud	Broader neural-data applications	Enterprise research relationships
Muse	Consumer brain-sensing devices	Expanded neurotechnology services	Consumer distribution and subscriptions

Will BCI companies make more money from hardware or software?

The strongest BCI businesses will probably make money from both, with the hardware creating the customer relationship and software keeping it valuable for years.

We can already see the model forming in non-invasive systems. Emotiv sells the sensor and then charges professional users for deeper recording and analysis tools. Kernel supplies the measurement infrastructure and sells recurring cloud capacity. Muse sells a wearable and then charges for extra coaching and analytics. Emotiv, Kernel and Muse all pair hardware with paid software, and we compare which business models are winning in our neurotech business models report.

Implanted BCI could push this model much further.

A neural implant may stay with a patient for years. During that time, the decoder can be updated, recalibrated and improved. The patient may need new applications, clinical support, device management and potentially cloud processing. Better models could also emerge as the company learns from a growing installed base.

Recent Neuralink work points directly toward that type of future. As seen above, the company is now using tens of thousands of hours of neural recordings to pretrain decoders that remain useful for longer periods without recalibration. Better software can therefore increase the value of hardware that is already implanted.

The attractive part is the recurring relationship. The difficult part is everything around it: regulation, surgery, manufacturing, clinical support and long-term liability.

NeuroPace again gives us a useful reality check. Its RNS gross margin exceeded 80% in 2025, yet the company still posted a roughly $5 million adjusted EBITDA loss for the full year.

Excellent device margins do not make the rest of a medical-device company cheap to run.

So how do brain-computer interface companies actually make money today?

Brain-computer interface companies currently make real commercial money mostly from research hardware, non-invasive EEG systems, software subscriptions, neuroscience infrastructure and adjacent medical products; implanted computer-control BCIs are still mainly financed by investors.

That is the clearest answer we can give today.

The commercial end of the market is already quite concrete. OpenBCI sells products ranging from a $1,249 acquisition board to a $42,980 multimodal research headset. Emotiv combines $399-$2,000-plus EEG hardware with professional software that can cost more than $1,000 per year. Kernel sells cloud infrastructure around its brain-imaging systems. Muse sells hundreds-of-dollars consumer devices with recurring Premium subscriptions. Blackrock has equipment in more than 1,000 laboratories.

The implanted end is advancing fast but has not caught up economically. Neuralink now has 21 clinical participants and a rapidly expanding neural-data operation. Paradromics has demonstrated real-time open-ended communication with its first long-term Connexus participant. Precision has a cleared cortical array and is starting to build a commercial bridge toward its full implant. CMS is even working through the procedure-coding questions that would eventually help hospitals bill for BCI implantation.

Those developments bring the market closer to real medical sales, but they do not suddenly turn clinical-stage implants into mature businesses.

The companies with the most convincing economics right now are the ones that can charge for something before the ultimate BCI is finished. Research systems, data tools, subscriptions and adjacent neurotechnology provide revenue while the harder medical products work through trials and reimbursement.

If implanted BCIs eventually reach routine clinical use, the money could become much larger per patient. Until then, today's BCI economy is mostly built around giving researchers and clinicians better access to the brain rather than selling brain implants at scale.